Comparative study between Embosphere® and Marine gel® as embolic agents for chemoembolization of hepatocellular carcinoma

Table 3 Adverse events and toxicities according to the treatment group

	Total (n = 70)	Embosphere (n = 33)	Marine gel (n = 37)	P value
Postembolization syndrome	25	12 (36.4)	13 (35.1)	0.915
Fever	1	1	0	0.286
Nausea/vomiting	6	2	4	0.479
Pain	23	11	12	0.448
Unscheduled hospital visit	2	1	1	0.935
Laboratory toxicity (90 d)
PT-INR (grade 0/1/2)	69/1/0	32/1/0	37/0/0	0.286
Albumin (grade 0/1/2)	67/3/0	32/1/0	35/2/0	0.624
Total bilirubin (grade 0/1/2)	63/5/2	30/2/1	33/3/1	0.811
AST (grade 0/1/2/3)	58/11/0/1	26/7/0/0	32/4/0/1	0.394
ALT (grade 0/1/2/3)	63/5/1/1	30/2/1/0	33/3/0/1	0.811
Alkaline phosphatase (grade 0/1/2)	67/3/0	33/0/0	34/3/0	0.095
Biloma	0	0	0	1.0
Liver abscess	0	0	0	1.0
Biliary duct dilation	0	0	0	1.0
Focal hepatic parenchymal infarct	1	1	0	0.286

PT: Prothrombin time; INR: International normalized ratio; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase. Number in parentheses is percentage.